Impaired Hemorheology in Exacerbations of COPD

Table 1

Laboratory data of the groups.

Parameter	Control group; ( = 12)	Newly diagnosed patient group		Exacerbation group; ( = 16)
		Before treatment; ( = 13)	After treatment; ( = 13)
Hb (g/dl)	15.24 ± 1.75	15.54 ± 1.82	15.28 ± 1.51	13.57 ± 2.2	0.052	0.033
Hct (%)	44.95 ± 5.42	47.45 ± 6.17	45.78 ± 3.88	40.93 ± 6.3	0.013	0.045
RBC (m/µL)	5.06 ± 0.61	5.21 ± 0.74	5.05 ± 0.55	4.57 ± 0.82	0.149	0.106
MCV (fL)	88.96 ± 3.73	91.41 ± 6.57	91.08 ± 5.81	90.13 ± 6.65	0.607	0.804
MCH (pg)	30.17 ± 0.97	29.98 ± 2.35	30.34 ± 2.07	29.83 ± 2.09	0.905	0.753
MCHC (g/dl)	33.95 ± 0.79	32.80 ± 1.07	33.32 ± 1.32	33.13 ± 1.41	0.060	0.246
WBC (K/uL)	7.41 ± 1.53	8.33 ± 1.85	8.66 ± 1.80	9.88 ± 5.40	0.228	0.231
Plt (K/uL)	214.64 ± 31.34	242.69 ± 49.77	242.38 ± 35.62	274.19 ± 154.62	0.263	0.175
Fibrinogen (mg/dL)	321.18 ± 115.24	312 ± 86.57	292.27 ± 74.51	446.44 ± 193.6	0.014	0.005
RDW (%)	12.81 ± 0.77	13.99 ± 1.23	13.93 ± 1.34	15.18 ± 1.6	0.001	0.0001

Values are expressed as means ± SD (Hb: hemoglobin, Hct: hematocrit, RBC: red blood cell, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, WBC: white blood cell, Plt: platelet count, and RDW: red blood cell distribution width). : difference between the control group, before treatment of newly diagnosed COPD, and the exacerbation group; : difference between the control group, after treatment of newly diagnosed COPD, and the exacerbation group; < 0.05: difference from control, < 0.05: difference from before treatment of COPD, and < 0.05: difference from after treatment of COPD.